ArticleInterdisciplinary sciences, computational life sciences2025
EnDM-CPP: A Multi-view Explainable Framework Based on Deep Learning and Machine Learning for Identifying Cell-Penetrating Peptides with Transformers and Analyzing Sequence Information.
Article in Interdisciplinary sciences, computational life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- SSEL-CPP: A SHAP-based feature-selection ensemble learning framework identifies molecular properties of cell-penetrating peptides.Protein science : a publication of the Protein Society · 2026Article
- De novo generation and in silico screening of anti-diabetic peptide candidates via a deep learning-attention framework with physicochemical feature fusion.Scientific reports · 2026Article
- Artificial intelligence-driven prediction and design of cell-penetrating peptides for advanced drug delivery system.Frontiers in pharmacology · 2026Article
- pCPPs-sADNN: predicting cell-penetrating peptides using self-attention based deep neural network.Scientific reports · 2025Article
- AMCL: supervised contrastive learning with hard sample mining for multi-functional therapeutic peptide prediction.BMC biology · 2025Article
- MFP-MFL: Leveraging Graph Attention and Multi-Feature Integration for Superior Multifunctional Bioactive Peptide Prediction.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cell-Penetrating Peptides (CPPs) are a crucial carrier for drug delivery. Since the process of synthesizing new CPPs in the laboratory is both time- and resource-consuming, computational methods to predict potential CPPs can be used to find CPPs to enhance the development of CPPs in therapy. In this study, EnDM-CPP is proposed, which combines machine learning algorithms (SVM and CatBoost) with convolutional neural networks (CNN and TextCNN). For dataset construction, three previous CPP benchmark datasets, including CPPsite 2.0, MLCPP 2.0, and CPP924, are merged to improve the diversity and reduce homology. For feature generation, two language model-based features obtained from the Transformer architecture, including ProtT5 and ESM-2, are employed in CNN and TextCNN. Additionally, sequence features, such as CPRS, Hybrid PseAAC, KSC, etc., are input to SVM and CatBoost. Based on the result of each predictor, Logistic Regression (LR) is built to predict the final decision. The experiment results indicate that ProtT5 and ESM-2 fusion features significantly contribute to predicting CPP and that combining employed features and models demonstrates better association. On an independent test dataset comparison, EnDM-CPP achieved an accuracy of 0.9495 and a Matthews correlation coefficient of 0.9008 with an improvement of 2.23%-9.48% and 4.32%-19.02%, respectively, compared with other state-of-the-art methods. Code and data are available at https://github.com/tudou1231/EnDM-CPP.git .
Indexed as
Identifiers
39714579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.